首站-论文投稿智能助手
期刊详情
《中国癌症研究(英文版)》
本刊主要是及时报道我国在肿瘤防治研究领域包括癌症基础理论研究和癌症预防、临床治疗研究方面的新进展、新成果,内容涉及肿瘤病因学与浒病学,实验肿瘤学、肿瘤细胞分子生物学,肿瘤病理学以及肿瘤影像诊断、肿瘤外科治疗、化学治疗、放射治疗、介入治疗、生物治疗和中西医结合治疗肿瘤等各分支学科,旨在促进国内外学术交流,提高我国癌症研究与癌症治疗水平。
{{ isqkjj == false ? "展开" : "收起" }}
出版周期:双月刊
语种:英文
影响因子:1.97
国内刊号:11-2591/R
国际刊号:1000-9604
♦ 主要栏目:基础研究 临床研究 短篇报告 个案报告 专题综述
♦ 获奖情况:1998年中国科协择优支持基础性、高科技学术期刊资助
♦ 收录情况: {{ e.split(":")[0] }} < 查看更新情况
♦ 期刊情况:CSCD,CSTPCD,SCI
♦ 主管单位:中国科学技术协会
♦ 主办单位:中国抗癌协会北京市肿瘤研究所
联系方式
主编:鄂征
电话:010-88196612;88196593
邮编:100142
邮箱:chjcacnr@126.com
地址:北京市海淀区阜成路52号
发文分析
发文类型:
{{ obj.kz7 == 1 ? "学术" : obj.kz7 == 2 ? "学术+科普" : obj.kz7 == 3 ? "科普" : "未知" }}
年刊文量:
{{ obj.wznum }}篇
单期页码:
{{ obj.maxpage }}页
发文地域:
{{ item.name }}({{ (item.bl * 100).toFixed(2) }}%)
机构特征:
{{ item.word }}
发文热门词:
{{ item.name }}
文章分类:
{{ item.key }}({{ (item.value * 100).toFixed(2) }}%)
{{ iswzfl == false ? "展开更多" : "收起全部" }}
{{ item.flname }}[{{ item.name }}]({{ (item.bl * 100).toFixed(2) }}%)
Chinese quality control indices for standardized diagnosis and treatment of gastric cancer (2022 edition)
Shen Li;Fei Shan;Xiaotian Zhang;Yongheng Li;Yu Sun;Lei Tang;Qi Wu;Wenjing Yang;Jincheng Yang;Yu An;Ming Deng;Jiafu Ji - Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiotherapy,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Endoscopy Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Office for Cancer Diagnosis and Treatment Quality Control,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
A multi-center, open-label, randomized, parallel-controlled phase Ⅱ study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han;Mingzhi Zhang;Huaqing Wang;Qingyuan Zhang;Wei Li;Miaowang Hao;Yuhuan Gao;Jie Jin;Hanyun Ren;Yun Tang;Xiaonan Hong;Xiaoyan Ke;Hang Su;Lin Gui;Jianmin Luo;Liangzhi Xie;Wenlin Gai;Yuankai Shi - Clinical Pharmacology Research Center,Peking Union Medical College Hospital,State Key Laboratory of Complex Severe and Rare Diseases,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Medical Oncology,Tianjin People's Hospital,Tianjin 300121,China;Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Oncology Department of Cancer Center,the First Hospital of Jilin University,Changchun 130021,China;Department of Hematology,Tangdu Hospital,Air Force Medical University,Xi'an 710038,China;Department of Hematology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Hematology,the First Affiliated Hospital of Zhejiang University,Hangzhou 310003,China;Department of Hematology,Peking University First Hospital,Beijing 100034,China;Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Lymphoma,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Hematology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Beijing Engineering Research Center of Protein and Antibody,Sinocelltech Ltd.,Beijing 100176,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao - Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
学者H指数区间
机构H指数区间
学术论文:{{ zhichengxiangqing.pkmark || 0 }}篇
科普文章:{{ zhichengxiangqing.hxmark || 0 }}篇
职称要求查看来源
职称说明
以上信息,由域田数据科技根据网络公开资料自动分析生成,仅供参考!